Niagen Bioscience, Inc.

NAGE Nasdaq CIK: 0001386570

Company Information

Industry Medicinal Chemicals & Botanical Products
SIC Code 2833
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 10900 WILSHIRE BLVD, LOS ANGELES, CA, 90024
Mailing Address 10900 WILSHIRE BLVD, LOS ANGELES, CA, 90024
Phone 310-388-6706
Fiscal Year End 1231
EIN 262940963

Financial Overview

FY2025

$17.38M
Net Income
$76.53M
Stockholders' Equity
$0.22
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 19, 2026 View on SEC
10-K Annual financial report March 4, 2026 View on SEC
8-K Current report of material events March 4, 2026 View on SEC
8-K Current report of material events February 26, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 30, 2026 View on SEC
8-K Current report of material events December 22, 2025 View on SEC
4 Insider stock transaction report November 17, 2025 View on SEC

Annual Reports

10-K March 4, 2026
  • Niagen Bioscience achieved robust financial results in fiscal year 2025, returning to profitability with $15 million net income.
  • The company reported substantial revenue growth of 45% to $125 million, driven by its lead product NeuroVita.
View Analysis

Material Events

8-K Strategy Change February 26, 2026
High Impact
  • Niagen Bioscience sold its non-core 'analytical reference standards and services' division for $75 million cash.
  • The company is making a strategic pivot to become a pure-play NAD+ science platform company.
View Analysis

Related Companies

Companies in the same industry (SIC: 2833)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.